Cambridge gene therapy startup Voyager Therapeutics just wrapped up a $60 million Series B round to advance its treatments for conditions of the CNS like ALS and Parkinson’s disease. Voyager is using the money to advance its five clinical and preclinical programs, as well as a platform developed around adeno-associated viruses.
New investors include Brookside Capital and Partner Fund Management, with participation from Wellington Management, Casdin Capital and two undisclosed blue chip investment funds. This round’s right on the heels of an impressive $45 million Series A from Third Rock, which was completed just about a year ago as the company launched.
Voyager’s gene therapies are in different stages of completion, with its Parkinson’s therapy the most advanced:
